Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Avandia Day Two Might Be Same Old Song Even With Broken RECORD

This article was originally published in The Pink Sheet Daily

Executive Summary

There may be more at stake for FDA, and the pharmaceutical industry in general, in how the advisory committees interpret the RECORD trial than there is for Avandia itself.

Related Content

Sentinel Initiative Needs Better Defined Goals, Outside Review Concludes
FDA Policy On Financial Conflicts Of Public Speakers At Advisory Panels Unchanged
Revenge Of The "Brain-Dead Kangaroos": Many Veterans Of 2007 Avandia Vote Come Down Harder On Drug In 2010
Avandia Can Be Saved With New Warnings and REMS, Advisory Cmte. Says
Avandia's TIDE May Come In Smaller
Qnexa Proposed REMS Focuses On Registry, Web-Based Physician Education
PhRMA CEO Castellani Brings Trade Group Leadership, CEO Management Skills To Job
Grassley And Baucus Turn Up Heat On GSK With Attack On Avandia Data Handling
Avandia Should Stay On Market, Committee Says
Avandia Should Stay On Market, Committee Says





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts